-
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
This is a prospective, randomized, placebo-controlled, multicenter study of patients with newly diagnosed glioblastoma (nGBM) to evaluate a peptide vaccine (SurVaxM) in emulsion with Montanide ...Phase
Interventional
-
A Single-Arm Phase 2 Study Of Daratumumab In Previously Treated Stk11/Lkb1 Mutated Non-Small Cell Lung Cancer
This is a single arm, signal finding study of daratumumab in metastatic NSCLC patients with an STK11/LKB1 mutation. Patients will have received previous standard ...Phase
Interventional
-
Site for A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Na ve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
Site for A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary ...Phase
Interventional
-
AN OPEN-LABEL MULTICENTER PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF CRG-022 A CD22-DIRECTED AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19-DIRECTED CAR T-CELL THERAPY
CD19-directed autologous CAR T-cell therapy has changed the treatment landscape for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Nonetheless, up to 60 ...Phase
Interventional
-
A Phase 2 Randomized Study to Evaluate the Optimized Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC - LIVIGNO-1
This Phase 2, open-label, randomized study evaluates the optimal livmoniplimab dose and the safety and efficacy of livmoniplimab in combination with budigalimab in locally advanced ...Phase
Interventional
-
Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom ...Phase
Interventional
-
Site for A022104 The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
Site for This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy ...Phase
Interventional
-
A single arm phase II study of ADjuvant Endocrine therapy subcutaneous Pertuzumab and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive HER2-positive breast cancer (ADEPT)
This is a single arm open-label phase II trial of adjuvant Fixed Dose Combination (FDC) of subcutaneous (SC) trastuzumab (H) plus pertuzumab (P) and endocrine ...Phase
Interventional
-
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid TumorsPhase
Interventional
-
A PHASE II OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND MFOLFIRINOX VERSUS MFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and ...Phase
Interventional
